Publications by authors named "Michael Teifel"

Claim this Profile
P
PEGylated Recombinant Ink Toxin Depletes Arginine and Lysine and Inhibits the Growth of Tumor Xenografts.
Alena M Wolkersdorfer, Birgit Bergmann, Juliane Adelmann, Matthias Ebbinghaus, Eckhard Günther, Michael Teifel

ACS Biomater Sci Eng· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial.
Violetta Csákváry, Nicola Ammer, Ekaterine Bakhtadze Bagci, Olena V Bolshova, Birgitte Bentz Damholt, Michael Teifel

Horm Res Paediatr· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Nina Hanke, Michael Teifel, Daniel Moj, Jan-Georg Wojtyniak, Hannah Britz

Cancer Chemother Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New ligands of the ghrelin receptor based on the 1,2,4-triazole scaffold by introduction of a second chiral center.
Mathieu Maingot, Anne-Laure Blayo, Séverine Denoyelle, Céline M'Kadmi, Marjorie Damian, Michael Teifel

Bioorg Med Chem Lett· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New trisubstituted 1,2,4-triazoles as ghrelin receptor antagonists.
Anne-Laure Blayo, Mathieu Maingot, Babette Aicher, Céline M'Kadmi, Peter Schmidt, Michael Teifel

Bioorg Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Julien Defaux, Maud Antoine, Cédric Logé, Marc Le Borgne, Tilmann Schuster, Michael Teifel

Bioorg Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current view on the mechanism of action of perifosine in cancer.
Joachim Fensterle, Babette Aicher, Irene Seipelt, Michael Teifel, Juergen Engel

Anticancer Agents Med Chem· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.
Julien Defaux, Maud Antoine, Marc Le Borgne, Tilmann Schuster, Irene Seipelt, Michael Teifel

ChemMedChem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.
Christian Bode, Lutz Trojan, Christel Weiss, Bettina Kraenzlin, Uwe Michaelis, Michael Teifel

Oncol Rep· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.
Sebastian Strieth, Martin E Eichhorn, Alexander Werner, Birgitta Sauer, Michael Teifel

Clin Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes.
Sebastian Strieth, Claudia F Nussbaum, Martin E Eichhorn, Martin Fuhrmann, Michael Teifel

Int J Cancer· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphology and transfection study of human microvascular endothelial cell angiogenesis: an in vitro three-dimensional model.
Jasmin Lienau, Cortina Kaletta, Michael Teifel, Kurt Naujoks, Kanti Bhoola

Biol Chem· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature.
Sebastian Strieth, Martin E Eichhorn, Birgitta Sauer, Brita Schulze, Michael Teifel

Int J Cancer· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels.
Senat Krasnici, Alexander Werner, Martin E Eichhorn, Marcus Schmitt-Sody, Sascha A Pahernik, Michael Teifel

Int J Cancer· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy.
Marcus Schmitt-Sody, Sebastian Strieth, Senat Krasnici, Birgitta Sauer, Brita Schulze, Michael Teifel

Clin Cancer Res· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
Rainer Kunstfeld, Georg Wickenhauser, Uwe Michaelis, Michael Teifel, Wolfgang Umek

J Invest Dermatol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis